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Abstract
Background: In this study, we aimed to compare the efficacy of corticosteroid trigger point injection (TPI) versus
extracorporeal shock wave therapy (ESWT) on inferior trigger points in the quadratus lumborum (QL) muscle.
Methods: In this single-blind randomized clinical trial, 54 low back pain patients with myofascial trigger points on
QL muscle were investigated. Participants were randomly allocated into two groups with A and B pockets. Patients
in group A underwent radial ESWT and received 5 treatment sessions (1 per week) and actually were not followed-
up. However, patients in group B received corticosteroid TPI and received one session of corticosteroid treatment
and followed-up for 4 weeks after injection. Oswestry Disability Index (ODI), visual analogue scale (VAS), pain
pressure threshold (PPT) and short form (36) health survey (SF-36) were measured in both groups before, two
weeks after and four weeks after intervention.
Results: The between group comparison indicated that corticosteroid TPI leaded to significant higher improvements
of ODI (P-value< 0.01), VAS (P value< 0.001), and PPT (P-value = 0.001) scores compared to the ESWT group at two-
week follow-up time-point. ESWT group recorded significant higher improvement of ODI (P-value< 0.01) and SF-36 (P-
value< 0.001) compared to the corticosteroid TPI at 4th week post treatment evaluation. At four-week follow-up time-
point, the patients in the ESWT group were 1.46 times more likely to achieve 30% reduction in VAS, 2.67 times more
likely to achieve 30% reduction in ODI, and 2.30 times more likely to achieve 20% improvement in SF-36 compared to
the participants in corticosteroid TPI group. These results refer to large effect size for all study outcomes in ESWT group
(d = 4.72, d = 1.58, d = 5.48, and d = 7.47 for ODI, PPT, SF-36, and VAS, respectively).
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Conclusion: Corticosteroid TPI was more effective compared to ESWT in short-term controlling of pain and disability
caused by myofascial pain syndrome of QL muscle. However, after 4 weeks treatment, ESWT further improved the
quality of life and disability and was related with more probability of achievement the minimal clinically important
difference concerning pain, disability and quality of life and large effect size for all study outcomes in treated patients
compared to corticosteroid TPI.
Trial registration: www.irct.ir, IRCT20100827004641N14, retrospectively registered 2019-01-19.
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Background
Low back pain (LBP) is a common health issue in all
over the world, especially in the industrialized countries.
Approximately 80% of people experience LBP at least
once in their life [1]. Although LBP initiates with mild
limited pain, it may cause complications in case of inci-
dents, in a way that nearly 15% of the patients with LBP
may be presentably disabled. Performing physical activity
and exercise therapy in LBP is paid much attention in
the last few decades [2, 3]. Too much using and strain-
ing of the quadratus lumborum (QL) muscle is one of
the main reasons of chronic LBP. This muscle is located
lateral to spine in the lumbar vertebrae region, which is
attached to the inferior edge of 12th rib and transverse
process of the first 4 lumbar vertebrae on the one side,
and medial surface of iliac crest on the other side. Myo-
fascial pain syndrome (MPS) of QL is among treatment
resistant etiologies of LBP [4].
Trigger point is a point with high irritability inside a
taut band of skeletal muscle, which can cause a certain
pattern of radiating pain and tenderness when exposed
to pressure or stretching [5–7]. Trigger points may be
organized in any muscle; however, trigger points are
more common in muscles involved in the body balance
[8]. Myofascial trigger point has a multifactorial etiology,
which most importantly includes psychological factors,
inappropriate biomechanics, and muscle overuse [5, 8].
There are several methods for resolving of myofascial
trigger points, including non-surgical interventions such
as NSAIDs, dry needling, avoiding severe activities, and
using physical modalities such as trigger point injection
(TPI) and extracorporeal shock wave therapy (ESWT)
[9]. Local analgesic, saline, corticosteroid, botulinum
toxin, and dry needling methods are diverse injection
methods that can be applied to deactivate the trigger
points [10]. Local corticosteroid injection, inhibits the
phagocytosis and synthesis and release of inflammatory
chemical mediators and enzymes, and in this way can
exert anti-inflammatory effects while protecting the
patient from systemic side effects [11].
Since mid-1990s, shockwave is used in the treatment
of some musculoskeletal disorders such as lateral epi-
condylitis, shoulder calcification, and plantar fasciitis. In
ESWT, waves are formed with electromagnetic, piezo-
electric, and electrohydraulic methods. ESWT has been
considered as an alternative therapeutic approach for
MPS over the last 25–30 years, especially in the subjects
with symptoms resistant to conventional treatments
[12]. Hye Min Ji et al. [13] assessed the efficacy of ESWT
in the upper trapezius MPS and established that, ESWT
significantly decreased the pain intensity in treated
subjects.
So far, evidences on ESWT’s efficiency in QL muscle
are limited, and on the other hand the effect of ESWT
has not been compared with corticosteroid injection in
the lower back trigger points in nonspecific LBP. Hong
et al. [14] has recently compared the effectiveness of
ESWT and TPI for the treatment of MPS in the QL;
however, this study was a retrospective study, not a ran-
domized clinical study, and the participants’ interests to
the treatment technique may lead to confounded and
biased findings. Thus, we decided to the prospectively
compare the effectiveness of corticosteroid TPI and
ESWT in the inferior trigger points of the QL muscle.
Methods
Study design and setting
This study was an assessor-blinded, parallel-group, ran-
domized controlled trial with a 1:1 allocation ratio,
which was conducted at the Shohada Educational
Hospital in 2019, Tabriz, Iran. The study was approved
by the ethics committee of Tabriz University of Medical
Sciences. The research was conducted in terms of the
Helsinki Declaration, and informed written consent was
obtained from all participants. The CONSORT guide-
lines were conformed and the CONSORT diagram was
applied to demonstrate the flow of participants at each
stage of the study.
Study sample
The inclusion criteria were the presence of LBP for at
least three months [15, 16], at least one local tenderness
or active trigger point in the inferior anatomic region of
the QL muscle, which can be distinguished by pain, re-
ferred pain, and local twitch response by gentle manual
compressing [17–19] and a palpable nodule along with a
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taut band in the selected muscles based on the anatom-
ical position (MPS established in terms of the criteria
specified by Travel and Simon) [20], normal neurologic
examination, visual analogue scale (VAS) above 4 points
(out of 10), willingness to participate in the study, and
not receiving concurrent medical treatment.
Exclusion criteria were any type of injection or physical
treatment in the last 3months, sacroiliac joint problems
based on the physical examination, bertolotti syndrome,
hemorrhagic disorders, systemic infection or local infec-
tion at injection site, positive history of significant allergic
reactions to corticosteroids, pregnancy, diabetes, dynamic
listhesis, and body mass index (BMI) 30 kg/m2 and more.
Assignment of interventions
Participants were randomized by a statistician in clinic
with a 1:1 ratio, using Random Allocation Software.
Blocking method was used to confirm similar numbers
of participants who were allocated to the two treatment
arms. Random permuted block sizes of 4–6 were used.
The participant allocations were kept in sealed opaque
envelopes. A statistician, who was blinded to all clinical
data, performed the allocation. The individuals perform-
ing the clinical tests and also the person who performed
all the statistical analyses were blinded to group alloca-
tion. Neither the participants nor the person performing
the intervention were blinded.
Intervention
Patients in ESWT group, received five sessions of radial
shock wave therapy (rESWT) (one session per week)
with ballistic, high energy pulses through three weeks via
a Zimmer enPulsPro Medizin System Gmbh, Germany.
Patients’ position was prone, affected side was exposed,
and the applicator was directed in the most tender point
over the lower back affected side and gently moved
around the trigger point in each treatment session. Trans-
mission gel was applied between the device and the sub-
jects’ skin with no local anesthetic. rESWT was used with
shockwaves of 1500 pulses/session with an energy flux
density of 0.1 mj/mm2/min, energy level of 2–4, a fre-
quency of 10–16Hz, and pulse rate of 160/min in total,
based on the recommended treatment protocol of
enPulsPro System for myofascial syndrome.
The participant in corticosteroid TPI group was posi-
tioned in a prone situation and trigger points on the QL
were checked. Injections on trigger points were done
based on the method explained by Travell and Simons
[20, 21]. Antisepsis was applied and trigger point was
confirmed to be held immobilize between two fingers.
Then, a sterile 5 ml syringe containing 40mg triamcino-
lone + 2ml of lidocaine 2% was inserted with an angle of
90° into the skin through the skin and progressed on-
ward to a depth of 3–3.5 cm till the trigger point was
grasped. The trigger point was recognized by local
twitch reaction or tightening of the taut band with pain.
Then, the needle was retreated to the subcutaneous tis-
sue and forwarded to different directions (superiorly, in-
feriorly, laterally, and medially) with fan-shaped syringe
turning after some material was thrown in after negative
aspiration [22, 23]. At most, two trigger points were
injected in each participant. To promote hemostasis, the
inserted locations were compressed by hand for two mi-
nutes. Subsequently, the participant was altered to a su-
pine situation and remained for duration of ten minutes.
Stretching exercises were instructed for participants in
both groups and activities of daily living modifications
(e.g. avoiding heavy lifting, walking long distances, and
high-impact exercises) were also taught. Patients were
advised to use only acetaminophen for pain relief in the
event of severe pain and the number of pills used was
documented. A diary was applied to note the stretching
exercises dates and durations (minute).
Outcome measures
Study variables included VAS, pressure-pain threshold
(PPT), Oswestry disability index (ODI), and the short form
(36) health survey (SF-36), which were measured before
the intervention, two weeks after, and four weeks after the
intervention. The study outcome was defined as a signifi-
cant reduction in pain intensity based on VAS, or a signifi-
cant improvement in Lumbar functional status based on
ODI, or an improvement in PPT based on a digital alg-
ometer measurement or an increasing in quality of life
based on SF-36 score.
Visual analogue scale (VAS)
Pain intensities in both groups were assessed using VAS,
which is a widely used test in pain assessment studies
with acceptable reliability and validity (0–10 cm pain
scale: 0 = none and 10 = unbearable) [24]. Accordingly, a
minimal improvement of 30% in VAS was defined as
Minimal Clinically Important Difference (MCID) [25].
Pressure-pain threshold (PPT)
A digital algometer (Wagner Instruments, Greenwich, CT,
USA) enabled us to assess the PPT in trigger points of the
QL muscle [26]. Larger values indicate higher pain thresh-
olds. The algometer circular flat tip with 1.0 cm2 surface
was slowly pushed upright to the skin over the trigger
points until the subject’s expressed sensation altered from
compression to the pain. The exerted pressure was enlarged
at a rate of 1 kg/cm2. Participants were requested to inform
the assessor by saying “yes” when the pain was perceived.
The measurements were implemented three times with 40
s intervals, and the mean average value was considered
(Fig. 1) [27]. A mean difference of 0.94 kg/cm2 in PPT was
defined as MCID [28].
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Oswestry disability index (ODI)
Lumbar functional status was assessed using ODI ques-
tionnaire, which is a routinely used index for LBP, and
the reliability and validity of its Persian version have
been established. ODI ranges from 0 to 100, with lower
scores indicating less severe symptoms [29]. This ques-
tionnaire consists of 10 items, and each item is scored
from 0 to 5. To calculate the disability parentage, the
score was divided to 50 and multiplied by 100. The score
ranges from a minimum of zero, which indicates no dis-
ability, up to a maximum of 50, which indicates 100%
disability. The items involve “pain intensity, personal
care, lifting, walking, sitting, standing, sleeping, sex life,
social life, and traveling”. A minimal improvement of
30% in ODI was considered as MCID in the present
study [28].
Quality of life (QoL)
Quality of life status was evaluated using the short form
(36) health survey (SF-36) questionnaire, which consists
of 36 items regarding the quality of life with respect to
the physical and emotional aspects. Likert scales and
yes/no options were used to assess function and well-
being on this 36-item questionnaire. To score the SF-36,
scales are standardized with a scoring algorithm to ob-
tain a score ranging from 0 to 100. Higher scores indi-
cate better health status. Also, the scoring method was
mentioned in the form. This questionnaire has been
translated to Persian and the reliability and validity of
the Persian version of the questionnaire have been
assessed [30]. A minimal improvement of 20% in SF-36
scores were defined as MCID in the present study [31].
Side effects and adverse events
At the second and fourth weeks of follow-up, partici-
pants completed a form on the side effects they had
endured with study interventions. The form asked about
frequently expressed side effects (such as discomfort).
Sample size
The study sample size was determined regarding to the
main outcome of the study: “improvement in the VAS”.
Considering the VAS, a group with a sample size of 21
was necessary to achieve a between group mean differ-
ence of 1.43 points [32], on a significance level (alpha) of
0.05 and power of 97.5%. Considering 25% loss to
follow-up rate, a sample size of 27 patients in each treat-
ment group was determined for this trial [33, 34].
Statistical analysis
All information obtained from the study were screened
and analyzed by the SPSS 20.0 software (IBM SPSS Sta-
tistics for Windows, Version 20.0. Armonk, NY: IBM
Corp). Normality assumption analysis was performed
using of Kolmogorov Smirnov test. In bivariate analysis,
independent samples t-test was used for numerical
scales, and χ2 test or fisher’s exact test were used for cat-
egorical scales. To evaluate within group changes and
between group differences, two-way mixed ANOVA test
along with the sidak posthoc as adjustment procedure
were used. Intention-to-treat (ITT) principle in which
study participants are analyzed according to their ran-
domized assignment even if they were lost to follow up
or failed to adhere to the protocol was applied in this
study.
We reported effect size in terms of Cohen’s d for all
outcome measures. We used on benchmarks suggested
by Cohen to interpret the calculated effect sizes as small
(d = 0.2), medium (d = 0.5), and large (d = 0.8) [35]. The
Number Needed to Treat (NNT) is a measure of treat-
ment effect, which represent the number of patients
Fig. 1 Algometry measurement on inferior trigger points in the
quadratus lumborum muscle
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need to be treated to prevent one additional bad out-
come. RR is used to compare the risk of an outcome
when receiving a medical treatment versus no treatment
(or placebo). Risk ratio (RR) and NNT along with 95%
CI were calculated. To produce the 95% CI, the exact
method of estimation was used. In this trial, the general
strategy for analysis was based on an ITT approach. A P
value less than 0.05 was considered as statistically sig-




A total of 73 patients who were referred with the domin-
ant complaints of LBP from January to December 2019
were included in this study. Out of these 73 patients, 19
were excluded, including 10 failures to confirm the in-
clusion criteria, 4 conforming the exclusion criteria, and
5 declined to participate in the study. Eventually, 54 pa-
tients were enrolled in the study. The recruited patients
were randomly assigned to ESWT and TPI groups, in a
ratio of 1:1. No patient was excluded from the analysis;
finally, there were 27 patients in each group. The study
flowchart is presented in Fig. 2. Additional basic and
demographic characteristics of the participants are
shown in Table 1. None of the participants used acet-
aminophen or any other pain killers through the study
period.
Effects of the intervention
There was a significant interaction between time points
(0, 2 week, 4 week) serving as the within-group factor and
group (ESWT vs. corticosteroid TPI) as the between-group
factor with regard to study variables (ODI: F (time*group)
(2, 104) = 26.42, P < 0.001; PPT: F (time*group) (2, 104) =
14.87, P < 0.001; SF-36: F (time*group) (2, 104) = 9.96,
P < 0.001; VAS: F (time*group) (2, 104) = 30.90, P < 0.001).
As there is a statistically significant interaction, we needed
to determine the difference between study groups at each
level of time factor. The results on the clinical outcomes
are shown in Tables 2 and 3.
Within group comparison of clinical outcomes
The within group comparisons revealed that, at two
weeks follow-up time-point, both groups experienced
statistically significant clinical benefits in their ODI
(ESWT: two-week MC (95% CI); P-value: 6.37 (4.34 to
8.40); < 0.001, four-week MC (95% CI); P-value: 8.18
(6.02 to 10.35); < 0.001, Corticosteroid TPI: two-week
MC (95% CI); P-value: 10.41 (8.38 to 12.43); < 0.001,
four-week MC (95% CI); P-value: 4.04 (1.87 to 6.20); <
0.001), PPT (ESWT: two-week MC (95% CI); P-value:
5.33 (3.43 to 7.23); < 0.001, four-week MC (95% CI);
P-value: 6.22 (4.26 to 8.19); < 0.001, Corticosteroid
TPI: two-week MC (95% CI); P-value: 9.30 (7.40 to
11.20); < 0.001, four-week MC (95% CI); P-value: 4.96
(3.00 to 6.93); < 0.001), SF-36 (ESWT: two-week MC
Fig. 2 Flowchart
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(95% CI); P-value: 7.33 (4.18 to 10.48); < 0.001, four-
week MC (95% CI); P-value: 9.41 (5.93 to 12.88); <
0.001, Corticosteroid TPI: two-week MC (95% CI); P-
value: 5.78 (2.63 to 8.93); < 0.001, four-week MC
(95% CI); P-value: 1.70 (− 1.76 to 5.18); < 0.001), and
VAS scores (ESWT: two-week MC (95% CI); P-value:
1.81 (1.18 to 2.44); < 0.001, four-week MC (95% CI);
P-value: 2.52 (1.90 to 3.13); < 0.001, Corticosteroid
TPI: two-week MC (95% CI); P-value: 3.70 (3.07 to
4.33); < 0.001, four-week MC (95% CI); P-value: 1.78
(1.16 to 2.39); < 0.001) compared to the before treat-
ment, which lasted for 4 weeks after the treatment.
The only considerable point was in the quality of life
of the patients under corticosteroid injection. Al-
though corticosteroid injections could improve the
patient’s quality of life within two weeks after the
treatment (P value< 0.001), this change did not last
for one month (P value = 0.546). The ESWT group
reached a peak in therapeutic effects four weeks after
the treatment, and the changes were statistically sig-
nificant compared to before treatment. Reaching a
peak in therapeutic effects for corticosteroid injection
group occurred two weeks after the treatment, and
the changes were statistically significant compared to
before treatment (Table 2).
Between group comparison of clinical outcomes
The between group comparison at two weeks after treat-
ment indicated that, corticosteroid TPI group recorded
statistically significant more improvements of ODI, VAS,
and PPT scores compared to the ESWT group (All P
value< 0.05). Compared to the TPI group, participants in
the ESWT group experienced significantly more im-
provements in the ODI and SF-36 at 4th week post
treatment evaluations (P value< 0.05) (Table 3).
Table 1 Demographic and baseline characteristics comparison
of patients with chronic LBP with trigger point on quadratus







Gender (female) 20 (74.1%) 17 (63.0%) 0.379a
Age, yrs 44.74 ± 9.34 45.04 ± 11.86 0.919b
BMI, kg/m2 27.47 ± 1.44 26.20 ± 2.06 0.110b
Note: The data are presented as mean ± standard deviation or
frequency (percentage)
Abbreviation: ESWT Extracorporeal shockwave, TPI Trigger point injection, BMI
Body mass index
Symbol: a P obtained from Chi-Square test, bP obtained from Independent
samples t-test
Table 2 Mean Changes from the baseline in the clinical values of patients with chronic LBP with trigger point on quadratus
lumborum muscle within the each group of ESWT or corticosteroid TPI (n = 54)
Clinical value ESWT(n = 27) Corticosteroid TPI (n = 27)
Mean ± SD MC (95% CI)
P value †
Mean ± SD MC (95% CI)
P value †
ODI Before 22.44 ± 1.44 Reference 23.93 ± 1.27 Reference
Week 2 16.07 ± 1.29 6.37 (4.34 to 8.40)
< 0.001
13.52 ± 1.13 10.41 (8.38 to 12.43)
< 0.001
Week 4 14.26 ± 1.32 8.18 (6.02 to 10.35)
< 0.001
19.89 ± 1.13 4.04 (1.87 to 6.20)
0.001
PPT Before 28.04 ± 0.75 Reference 29.41 ± 0.47 Reference
Week 2 33.37 ± 1.21 5.33 (3.43 to 7.23)
< 0.001
38.70 ± 0.83 9.30 (7.40 to 11.20)
< 0.001
Week 4 34.26 ± 1.23 6.22 (4.26 to 8.19)
< 0.001
34.37 ± 0.70 4.96 (3.00 to 6.93)
< 0.001
SF-36 Before 74.59 ± 1.35 Reference 73.78 ± 1.30 Reference
Week 2 81.93 ± 1.53 7.33 (4.18 to 10.48)
< 0.001
79.56 ± 1.46 5.78 (2.63 to 8.93)
< 0.001
Week 4 84.00 ± 1.48 9.41 (5.93 to 12.88)
< 0.001
75.48 ± 1.08 1.70 (− 1.76 to 5.18)
0.546
VAS Before 7.63 ± 0.27 Reference 7.22 ± 0.26 Reference
Week 2 5.81 ± 0.25 1.81 (1.18 o 2.44)
< 0.001
3.52 ± 0.35 3.70 (3.07 to 4.33)
< 0.001
Week 4 5.11 ± 0.36 2.52 (1.90 to 3.13)
< 0.001
5.44 ± 0.27 1.78 (1.16 to 2.39)
< 0.001
Abbreviations: ESWT Extracorporeal shockwave, TPI Trigger point injection, SD standard deviation, MC mean change, CI confidence interval, ODI Oswestry disability
index, PPT Pressure Pain Threshold, SF-36 Short Form (36) Health Survey, VAS Visual Analogue Scale
Symbols: †P values obtained from Mixed ANOVA test
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Study outcomes evaluation
Based on the commonly used interpretation of the
Cohen’s d values, the results refer to large effect size for
all study outcomes in ESWT group (d = 4.72, d = 1.58,
d = 5.48, and d = 7.47 for ODI, PPT, SF-36, and VAS,
respectively).
The results showed that 59.31% of patients in the
ESWT group achieved the primary outcome (achieving
> 30% reduction from base line at 4th week follow up)
versus 25.9% in the corticosteroid TPI group: 16
(59.31%) vs. 7 (25.9%), respectively; RR = 1.46 with 95%
CI = 1.04 to 2.19; NNT = 3 with 95% CI = 1.85 to 14.4;
P = 0.013). NNT = 3 indicates that we would, on average,
have to teat 3 patients for 1 patient to have been experi-
enced 30% or more pain relief at 4th week follow up
(Table 4).
The number of the patients achieved MCID concern-
ing ODI was significantly higher in ESWT group. The
patients in the ESWT group were 2.67 times more likely
to achieve 30% reduction in ODI compared to the cor-
ticosteroid TPI group: 17 (63.0%) vs. 4 (14.8%); RR =
2.67 with 95% CI = 1.53 to 4.66; NNT = 2 with 95% CI =
1.35 to 3.61 (P < 0.001). For additional evaluation of the
effectiveness of ESWT, we calculated the NNT to
achieve 30% or more reduction in ODI. An NNT = 2 for
ODI indicates that if two patients are treated with the
ESWT, one would achieve MCID concerning ODI at 4th
week follow up and was statistically significant compared
with corticosteroid TPI (Table 4).
The number of the patients achieved MCID regarding
PPT (a mean difference of 0.94 kg/cm2) in the ESWT
group was more than the corticosteroid TPI group,
Table 3 Number of patients achieved study outcomesa and comparison of relative risk (RR) and number needed to treat (NNT)
between the two groups based on study outcomes (n = 54)
Clinical Values ESWT (n = 27) Corticosteroid TPI (n = 27) MD (ESWT-Corticosteroid)(95% CI)
P Value †Mean ± SD Mean ± SD
ODI Week 2 6.37 ± 0.75 10.41 ± 0.89 −4.56 (−6.01 to − 0.89)
0.007
Week 4 8.18 ± 1.05 4.04 ± 0.66 4.63 (1.14 to 8.11)
0.002
PPT Week 2 5.33 ± 0.76 9.30 ± 0.78 −4.33 (− 7.27 to − 3.40)
0.001
Week 4 6.22 ± 0.89 4.96 ± 0.69 1.11 (− 1.94 to 3.72)
0.379
SF-36 Week 2 7.33 ± 1.35 5.78 ± 1.20 2.37 (− 6.62 to 1.87)
0.672
Week 4 9.41 ± 1.71 1.70 ± 1.02 8.12 (4.83 to 12.20)
< 0.001
VAS Week 2 1.81 ± 0.16 3.70 ± 0.32 −2.30 (−3.16 to − 1.43)
< 0.001
Week 4 2.52 ± 0.29 1.78 ± 0.19 0.71 (−0.36 to 1.23)
0.109
Abbreviations: ESWT Extracorporeal shockwave, TPI Trigger point injection, SD standard deviation, MD mean difference, CI confidence interval, ODI Oswestry
disability index, PPT Pressure Pain Threshold, SF-36 Short Form (36) Health Survey, VAS Visual Analogue Scale
Symbols: †P values obtained from Mixed ANOVA test
Table 4 Comparison of Relative Risk (RR) and Number needed to treat (NNT) between the two groups based on study outcomes in
participants (n = 54)
Outcome a ESWT (n = 27) Corticosteroid TPI (n = 27) P value† RR (95% CI) NNT (95% CI)
ODI 17 (63.0%) 4 (14.8%) < 0.001 2.67 (1.53 to 4.66) 2 (1.35 to 3.61)
PPT 23 (85.20%) 18 (66.70%) 0.111 1.82 (0.84 to 2.18) 5.4 (2.54 to 22.4)
SF-36 10 (37.0%) 1 (3.7%) 0.002 2.30 (1.62 to 43.26) 2 (1.35 to 3.45)
VAS 16 (59.3%) 7 (25.9%) 0.013 1.46 (1.04 to 2.19) 3 (1.85 to 14.4)
Note: The data are presented as frequency (percentage)
Abbreviations: ESWT Extracorporeal shockwave, TPI Trigger point injection, RR Relative risk, NNT Number Needed to Treat, CI confidence interval (calculated using
exact method), ODI Oswestry disability index, PPT Pressure Pain Threshold, SF-36 Short Form (36) Health Survey; VAS: Visual Analogue Scale
Symbols: aThe outcomes is defined as at least 30% reduction in the final score (after 4 weeks) of VAS compared with the baseline score, OR at least 30% reduction
in the final score (after 4 weeks) of ODI compared with the baseline score, OR a mean difference of 0.94 kg/cm2 (after 4 weeks) of PPT compared with the baseline
score, OR at least 20% increase in the final score (after 4 weeks) of SF-36 compared with the baseline score; †obtained from χ2 Chi-Square test or Fisher’s
exact test
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however, the result was not statistically significant be-
tween the study groups (23 (85.20%) vs. 18 (66.70%);
RR = 1.82 with 95% CI = 0.84 to 2.18; NNT = 5.4 with
95% CI = 2.54 to 22.4; P = 0.111) (Table 4).
The between group differences were statistically sig-
nificant in favor of the other outcome, achieving 20%
improvement (MCID) in SF-36 (10 (37.0%) vs. 1 (3.70%);
RR = 2.30 with 95% CI = 1.62 to 43.26; NNT = 3 with
95% CI = 1.85 to 14.4; P < 0.01). For every three patients,
ESWT cause one patient to achieve 20% or more im-
provement in SF-36 (Table 4).
Side effects and adverse events
No clinically important adverse events, side effects, or
severe complications (e.g., hematomas and other abnor-
mal musculoskeletal events), which required medical
interference, were stated in either groups.
Discussion
In present study, we compared the efficacy of rESWT
(shockwaves of 1500 pulses/session with an energy flux
density of 0.1 mj/mm2/min and a frequency of 10–16
Hz) and corticosteroid TPI (40 mg triamcinolone) in al-
leviating pain and improving disability, PPT and quality
of life in the patients with MPS in the QL muscle, and
found that corticosteroid TPI resulted in significantly
higher improvements of disability, pain intensity and
PPT compared to the ESWT at two weeks follow-up
time-point. However, after 4 weeks, participants in the
ESWT group experienced further improvements regard-
ing the disability and quality of life compared to the cor-
ticosteroid TPI group. Accordingly, this provides the
evidence of the short-term beneficial effects of cortico-
steroid injection on pain intensity, PPT and disability.
However ESWT was more effective in management of
disability and improving the quality of life at one-month
follow-up after treatment.
LBP is the second most prevalent condition that
affects adult populace [36]. If this disorder is left un-
treated, it may significantly disturb quality of life in
patients [37]. In general, management approaches of LBP
comprise pharmacological and non-pharmacological treat-
ments [38]. Pharmacological treatments have inadequate
efficacy and a wide range of adverse events [39]. There-
fore, present guidelines principally emphasis on the non-
pharmacological approaches [40].
ESWT has been considered as a noninvasive non-
pharmacological treatment of many musculoskeletal disor-
ders in recent decades, in spite of its uncertain mechanism
of action [41–43]. The utilization of rESWT in MPS has
not been completely investigated. Nonetheless, there is sev-
eral evidence concerning the beneficial effect of rESWT for
plantar fasciitis, calcific tendinitis and epicondylitis [44, 45].
The review of the existing literature reveals that, in spite of
the novelty and high acceptance, there are only a few of
randomized clinical trials (RCTs) on the effectiveness and
safety of ESWT in LBP patients [32, 46–48].
In a similar study to our trial, Hong et al. [14] com-
pared the efficiency of ESWT for a total of 3 times, at 3-
day intervals and TPI in 30 patients with MPS in the
QL. Contrary to the findings of the present study, ESWT
was found to be more effective than TPI for pain relief.
However, ESWT was not better than TPI with respect to
disability. While, in our study, TPI was found to be more
effective than ESWT in improving disability at 2nd week
assessment and ESWT was found to be more effective
than corticosteroid TPI in improving disability at 4th
week assessment. After 4 weeks of the treatment, higher
percent of the participants in ESWT group achieved
MCID concerning disability index. ESWT was related
with at least two time higher likelihood of such an im-
provement in treated patients compared to corticoster-
oid TPI. Two patients must be treated with the purpose
of expect that one patient will experience ≥30% im-
provement concerning disability at 4th week assessments
that was statistically significant compared to corticoster-
oid TPI.
Lee et al. [49] in comparison the effectiveness of
ESWT and TPI in 31 patients with MPS in the trapezius
muscle concerning decreasing pain intensity and im-
proving of PPT, found no significant differences between
ESWT and TPI in terms of VAS and PPT. In our study,
TPI was more effective than ESWT in improving pain
intensity and PPT at 2 week evaluations. These different
findings may be due to applying different intensities and
impulses of ESWT. However after 4 weeks, their effi-
ciency was comparable. A considerably greater percent-
age of participants treated with ESWT achieved MCID
concerning VAS score after 4 weeks of the treatment. In
other words, after 4 weeks treatment, participants in
ESWT group were more likely to have such an improve-
ment compared to corticosteroid TPI. Three patients
must be treated to anticipate that one patient would
experience ≥30% decrease in pain intensity at 4th week
assessments that was statistically significant compared to
corticosteroid TPI.
In other studies, ESWT has been established as an effi-
cient treatment approach in decreasing resting and
movement pain and disability, and also improving the
quality of life and depression compared to placebo [50]
and conservative physical therapies [47] in patients with
chronic LBP. In our study, significantly higher propor-
tion of participants treated with ESWT compared with
corticosteroid TPI achieved MCID concerning quality of
life at week 4 of study. After 4 weeks treatment, partici-
pants in ESWT group were at least two times more
likely to have such an improvement in SF-36 score. Two
patients must be treated with the purpose of expect that
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one patient will experience ≥20% improvement regard-
ing quality of life at 4th week assessments that was
statistically significant compared to corticosteroid TPI.
In the prospective, randomized study by Walewicz
et al. [51] on a total of 52 patients with LBP, rESWT
(2000 pulses; 2.5 bars; 5 Hz, 7 mins) twice a week for five
weeks (10 sessions) was predominantly effective in the
long-term management and provides a stable advanta-
geous effect for patients without unexpected relapse.
While, in short-term the pain relief was not considerable
immediately after rESWT.
Several studies have attempted to clarify the mechan-
ism of shock waves from the basic science and clinical
studies. The thorough mechanisms for its pain-relieving
and functional properties are not completely figured out.
MPS is a condition in which stimulation of trigger points
in the muscles can lead to referred discomfort and pain.
So, it is critical to remove the trigger points. The ESWT,
acting through electromagnetic stimulation mechanism,
generates waves with low energy level that can be im-
pressive by enhancing the blood circulation in the
treated location [13, 52]. The transferred waves lead to
tissue repair through making micro-traumas and releas-
ing of growth and molecular factors [53]. Additionally,
ESWT stimulates the A delta receptor, which provides
prompt neuro-stimulator conduction and this represses
C fiber. The C fiber induction slow neuro-stimulator
conduction; and therefore, its repression blocks the
nerve transmission [54]. Furthermore, it has been sug-
gested that ESWT can decrease the pain in the tissues
via selective demolition of the non-myelinated fibers and
is fruitful in decreasing the concentration of substance
P, in addition to decreasing the production of substance
P in the dorsal root ganglia [55, 56]. ESWT can also decline
the concentrations of the inflammatory cytokines (interleu-
kins (IL) and matrix metalloproteinase (MMP)) [57].
In spite of its relatively high cost (equipment and
space requirements), ESWT may be endorsed as a treat-
ment alternate for myofascial trigger points. ESWT has
numerous excellences to other approaches as follows: It
is non-aggressive, infection free, and easy for using in
outpatient backgrounds. Furthermore, it is probable to
adjust treatment protocol based on the acceptance and
compliance of patients. ESWT can be applied to larger
surface by moving the probe location. In general, the
safety of ESWT is evidently confirmed through the cu-
mulative data [58]. The important thing to be considered
is that, TPI is not always reliable of exhaustively address-
ing diffused several taut bands. In such cases, ESWT is
an applicable treatment approach, with wide exposure
and no post-injection discomfort.
This study has some recommendations for the use of
rESWT in management of patients with LBP because of
the MPS of QL. When rESWT is applied to manage the
complaints of patients with LBP because of MPS, it pro-
vides more beneficial effect concerning improving dis-
ability and quality of life in the medium term with a
stable effect compared to corticosteroid TPI. However,
in short-term the results are best for corticosteroid TPI
regarding pain reduction and improving disability and
PPT. That means rESWT does not result in significant
pain relief effects immediately after the treatment. We
recommend rESWT with 1500 pulses/session; energy
level of 2–4; 10–16 Hz, 7 mins; performed one session
per week for five weeks for patient with MPS of QL.
Limitations of this study were firstly the absence of a
control group to rule out the placebo effect, or the lack
of a group to receive both interventions. Secondly, be-
cause this study was performed for a short period of
time, it was not capable to entirely evaluate the long-
term effects of each intervention. Therefore, future trials
should be designed for a longer period of time to com-
pletely assess the effects.
Conclusion
In MPS patient with inferior trigger points of QL
muscle, corticosteroid TPI was more efficient than
ESWT in decreasing pain intensity and disability after 2
week treatment. However, after 4 week treatment, ESWT
was more efficacious than corticosteroid TPI in improv-
ing quality of life and disability and was related with
more likelihood of at least 30% decrease in pain intensity
and disability and at least 20% improvement in quality of
life in treated patients compared to corticosteroid TPI.
The number of patients who must be treated by ESWT
in order to expect that one patient will achieve such im-
provements in pain intensity; disability and quality of life
were 3, 2 and 2 over a 4 week treatment period that were
statistically significant compared to corticosteroid TPI.
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